Gilead Sciences, Inc. (GILD) had its ‘Buy’ rating reiterated by analysts at Citigroup (C) in a research note issued on Friday. The firm also raised the biopharmaceutical company’s price target to $139 from $111, saying management looks “very optimistic” that fiscal 2015 hepatitis C treatment volumes could increase significantly over fiscal 2014 rates globally. GILD […]
View the full post at: Notable Upgrades: Gilead Sciences (GILD), Ideal Power (IPWR), American Eagle Outfitters (AEO), Golar LNG Limited (GLNG), Apple (AAPL)